Anti-Human PD-1&CTLA-4 Reference Antibody (Volrustomig, RUO)
- Catalog number: BS11416
- Availability: In Stock
$482.00
- Ex Tax: $482.00
Description: Volrustomig (BS11416) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-kappa/kappa-lambda
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Programmedcelldeathprotein1,ProteinPD-1,hPD-1,PD1,PDCD1,CD279,CD152,CytotoxicT-lymphocyteprotein4,CTLA-4,CTLA4,CytotoxicT-lymphocyte-associatedantigen4
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CAS:2407760-40-9
Background: Danvilostomig is an anti-CTLA4/PDCD1 monoclonal antibody.
References:
1. Cancer immunotherapy using checkpoint blockade., PMID:29567705
2. The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870
3. Immune-related adverse events of checkpoint inhibitors., PMID:32382051
4. Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845
5. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113
6. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885
7. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160
8. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858
9. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360
5. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-kappa/kappa-lambda
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Programmedcelldeathprotein1,ProteinPD-1,hPD-1,PD1,PDCD1,CD279,CD152,CytotoxicT-lymphocyteprotein4,CTLA-4,CTLA4,CytotoxicT-lymphocyte-associatedantigen4
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CAS:2407760-40-9
Background: Danvilostomig is an anti-CTLA4/PDCD1 monoclonal antibody.
References:
1. Cancer immunotherapy using checkpoint blockade., PMID:29567705
2. The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870
3. Immune-related adverse events of checkpoint inhibitors., PMID:32382051
4. Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845
5. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113
6. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885
7. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160
8. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858
9. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360
5. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704
Note: For research use only. Not suitable for clinical or therapeutic use.
